Steroid-Independent Crohn's Disease Patients Also Benefit From Combination Therapy of Infliximab Plus Azathioprine

Gastroenterology

Volumn 131, Issue 4, 2006, Pages 1362-1363

  van den Brande, Jan M H ^a   Peppelenbosch, Maikel P ^b  

^a Laboratory for Experimental Internal Medicine   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; STEROID; THALIDOMIDE;

CLINICAL PRACTICE; CROHN DISEASE; DISEASE COURSE; HUMAN; LETTER; MAINTENANCE THERAPY; MEDICAL RECORD; MONOTHERAPY; PRIORITY JOURNAL;

EID: 33749344053     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2006.08.054     Document Type: Letter

References (1)

1. Lemann M., Mary J.Y., Duclos B., Veyrac M., Dupas J.L., Delchier J.C., Laharie D., Moreau J., Cadiot G., Picon L., Bourreille A., Sobahni I., Colombel J.F., and Groupe d'Etude Therapeutique des Affections Inflammatoires du Tube Digestif (GETAID). Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 130 (2006) 1054-1061